Study/Projects - Tuberculosis

Clinical Sites:

Dr. Vidya Mave is leading this clinical trial evaluating the safety and efficacy of a new recombinant BCG vaccine.

Assessing the Impact of the Fogarty HIV-TB Training Program at the Byramjee Jeejeebhoy Government Medical College, Pune, India

Post Date:

2018-01-19

Countries:

Clinical Sites:

This study was terminated in January 2021. It was funded by the Fogarty International Center at the U.S. National Institutes of Health. Johns Hopkins University was funded in 2013 to establish a new post-doctoral training program in HIV-TB epidemiology, clinical and...

Perceptions of HCWs on Barriers and Opportunities to Airborne Infection Control Guideline Implementation

Post Date:

2017-12-07

Countries:

Clinical Sites:

This study was terminated in December 2020 It was funded and conducted under the U.S. National Institutes of Health, Fogarty International Center. Led by Dr. Nishi Suryavanshi, this qualitative, cross-sectional study is assessing healthcare worker (HCW) perceptions about...

A5302: BioBank for Surrogate Marker Research for TB (B-SMART)

Post Date:

2017-11-21

Countries:

Clinical Sites:

This study was terminated September 1, 2021. This study is conducted under the AIDS Clinical Trials Group (ACTG) and funded by the U.S. National Institutes of Health. A5302 is a multi-center trial of the AIDS Clinical Trials Group (ACTG) in collaboration...

The Role of GeneXpert in Bacterial Diagnosis of Spinal Tuberculosis

Post Date:

2017-10-26

Countries:

Clinical Sites:

This study was teriminated June 19, 2019. It was funded by the Fogarty International Center at the U.S. National Institutes of Health. India has the maximum burden of tuberculosis (TB) in the world. In 2014, there were an estimated 9.6 million incident...

Characteristics Associated with Mobile Phone Usage among TB Populations in Pune, India

Post Date:

2017-10-02

Countries:

Clinical Sites:

With 8.6 million people affected worldwide in 2012, the control and prevention of tuberculosis (TB) has become an international priority. In order to reduce burdens and achieve global goals for TB control, new and innovative tools are necessary. With a growing number of mobile phone subscriptions...

Lipid Mediators of Inflammation in TB and TB-Diabetes

Post Date:

2017-10-02

Countries:

Clinical Sites:

This study was terminated August 1, 2019. It was funded and conducted under the U.S. National Institutes of Health and is nested within Impact of Diabetes on TB Treatment Outcomes. Dr. Jonathan Golub was the PI. Studies have shown that individuals with...

Targeting Mycobacterium Tuberculosis Persisters by Enhancing Stringent Response-specific Cellular Immunity

Post Date:

2017-09-11

Countries:

Clinical Sites:

C-TRIUMPH nested study begins to see if stringent response antigen is enhanced while treating drug-susceptible TB using the first-line anti-TB regimen.

Investigating Maternal Antibodies to Modify Infant Tuberculosis Acquisition

Post Date:

2017-08-29

Countries:

Clinical Sites:

New study in Pune, India, aims to identify the profile of TB antibodies between mothers and infants, and to see if the presence of antibodies lowers risk of infant infection.

Validation of Transcriptional Signature to Predict Active TB Disease among Advanced HIV Patients

Post Date:

2017-08-15

Countries:

Clinical Sites:

This study was terminated June 20, 2021. There have been tremendous advances in the diagnosis of patients with tuberculosis (TB) based on nucleic acid amplification of bacteria in the sputum. The GenXpert MTB/RIF provides results in 2 hours. However, in HIV-infected sputum...

Association of Lipid Mediators of Inflammation with TB Treatment Outcomes

Post Date:

2017-08-03

Countries:

Clinical Sites:

This study was terminated July 22, 2019. This study used stored samples from the Cohort for Tuberculosis Research by the Indo-US Medical Partnership (C-TRIUMPH), under the Regional Prospective Observational Research for Tuberculosis (RePORT) Network, an international TB...

Optimizing Treatment to Improve TBM Outcomes in Children: Substudy on Clinical Profile and CSF Biorepository of the Pediatric Suspected Meningitis Cases

Post Date:

2017-07-18

Countries:

Clinical Sites:

This sub-study is being led by PIs Dr. Kelly Dooley and Dr. Chhaya Valvi. Meningoencephalitis is associated with significant morbidity and mortality. Several viruses, bacteria, and fungal pathogens including Neisseria meningitidis, Streptococcus pneumoniae, Mycobacterium...

A5349: Rifapentine-containing Treatment Shortening Regimens for Pulmonary Tuberculosis: A Randomized, Open-label, Controlled Phase 3 Clinical Trial

Post Date:

2017-06-05

Countries:

Clinical Sites:

This study is conducted under the AIDS Clinical Trials Group (ACTG) and funded by the U.S. National Institutes of Health. This is an international, multicenter, randomized, controlled, open-label, 3-arm, phase 3 non-inferiority trial. Primary Objectives:...

Understanding Quality of Life during and Loss to Follow-up from Drug-Resistant Tuberculosis Treatment in Pune, India

Post Date:

2017-05-15

Countries:

Clinical Sites:

This study will examine a) risk factors for loss to follow-up from DR-TB treatment, b) actively trace DR-TB patients lost to follow-up from treatment and c) establish a prospective observational cohort of MDR-TB, XDR-TB and DS-TB patients as well as healthy controls nested within ongoing...

Risk Factors for Unfavourable Treatment Outcomes among Multidrug-Resistant Tuberculosis Patients in Public Sector Treatment in Pune

Post Date:

2017-03-29

Countries:

This study is funded and conducted under the U.S. National Institutes of Health, Fogarty International Center. This study seeks to identify risk factors associated with unfavourable treatment outcomes (death, treatment failure, default, XDR-TB) among multidrug-resistant...

MDR-TB Free: Monitoring Adverse Effects, Utilizing Resources Optimally, Knowing Resistance Patterns, and Treatment Strategy

Post Date:

2017-03-24

Countries:

Clinical Sites:

Hinduja Hospital

This study is also known as MDR-TB MUKT: Monitoring Adverse Effects, Utilizing Resources Optimally, Knowing Resistance Patterns, and Treatment Strategy. Purpose: To establish an observational cohort of MDR-TB cases and household contacts with accompanying biorepository at PD Hinduja National...

Biomarkers for Tuberculosis Diagnosis and Treatment Response

Post Date:

2017-03-24

Countries:

Clinical Sites:

This study is conducted by the Cohort for Tuberculosis Research by the Indo-US Medical Partnership (C-TRIUMPH) under the Regional Prospective Observational Research for Tuberculosis (RePORT) Network, an international TB consortium. Aims: ...

Impact of HIV and Diabetes Mellitus on TB Drug Resistance and Recurrence

Post Date:

2017-03-02

Countries:

Clinical Sites:

This study was terminated in January 2021. Tuberculosis (TB) is the leading cause of mortality globally. With increasing burden of HIV and diabetes mellitus (DM), there is a critical need to understand the microbial response and ensuing disease dynamics of TB in the HIV-infected and diabetic host...

Multicenter Study of the Accuracy of the BD MAX MDR-TB Assay for Detection of M. tuberculosis Complex and Mutations Associated with Resistance to Rifampin or Isoniazid

Post Date:

2017-03-01

Countries:

Clinical Sites:

In a multi-country study, we are assessing the accuracy of the BD MAX rapid MDR-TB assay to detect rifampin and isoniazid resistance.

TREAT Asia Observational Database

Post Date:

2017-02-09

Countries:

Clinical Sites: